DDAH I Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
L-NG-Monomethylarginine, Acetate Salt (L-NMMA) | 53308-83-1 | sc-200739 sc-200739A sc-200739B sc-200739C | 25 mg 100 mg 1 g 100 g | $90.00 $260.00 $800.00 $40378.00 | 3 | |
Nω-Methyl-L-arginine acetate (L-NMMA) is a competitive inhibitor of DDAH I. It competes with asymmetric dimethylarginine (ADMA) for binding to the active site of DDAH I. By mimicking the structure of ADMA, L-NMMA interferes with the enzymatic activity of DDAH I, preventing the normal conversion of ADMA to citrulline and methylamine. | ||||||
Ammonium metatungstate hydrate | 12333-11-8 | sc-239234 sc-239234A | 100 g 500 g | $95.00 $378.00 | ||
Ammonium metatungstate is a potent and selective inhibitor of DDAH I. It directly inhibits DDAH I activity, preventing the conversion of asymmetric dimethylarginine (ADMA) to citrulline and methylamine. The inhibition of DDAH I by AMT leads to elevated levels of ADMA, impacting nitric oxide synthase (NOS) activity and modulating NO signaling pathways. The modulation of DDAH I by AMT occurs at the catalytic site, restricting its enzymatic function and influencing NO signaling. | ||||||
L-Homocitrulline | 1190-49-4 | sc-269298 sc-269298A sc-269298B sc-269298C | 100 mg 1 g 10 g 25 g | $72.00 $250.00 $490.00 $1098.00 | 5 | |
L-Homocitrulline is a substrate analog and competitive inhibitor of DDAH I. Structurally resembling asymmetric dimethylarginine (ADMA), it competes with ADMA for binding to the active site of DDAH I. The competitive inhibition by L-homocitrulline interferes with the normal metabolism of ADMA, leading to altered nitric oxide (NO) signaling pathways. The chemical's action involves direct competition for the enzyme's active site. | ||||||
D-Aspartic acid | 1783-96-6 | sc-202562 | 1 g | $31.00 | ||
D-Aspartic acid is a competitive inhibitor of DDAH I. Similar to other substrate analogs, it mimics the structure of asymmetric dimethylarginine (ADMA) and competes for binding to the active site of DDAH I. The competitive inhibition by D-aspartic acid interferes with the normal metabolism of ADMA, leading to altered nitric oxide (NO) signaling pathways. The chemical's action involves direct competition for the enzyme's active site. | ||||||
7-Nitroindazole | 2942-42-9 | sc-3569 | 100 mg | $70.00 | 4 | |
7-Nitroindazole is a selective inhibitor of nitric oxide synthase (NOS). It indirectly inhibits DDAH I by reducing the availability of nitric oxide (NO). The reduction in NO levels impacts the feedback inhibition of DDAH I, leading to altered ADMA metabolism. The indirect inhibition by 7-nitroindazole involves modulation of the NO signaling pathway, influencing DDAH I activity and the levels of its substrate, asymmetric dimethylarginine (ADMA). | ||||||
S-Methylisothiourea sulfate | 867-44-7 | sc-3566 sc-3566A | 1 g 100 g | $20.00 $23.00 | 8 | |
S-Methylisothiourea sulfate is a potent and selective inhibitor of inducible nitric oxide synthase (iNOS). It indirectly inhibits DDAH I by reducing the availability of nitric oxide (NO). The reduction in NO levels impacts the feedback inhibition of DDAH I, leading to altered ADMA metabolism. | ||||||
Sodium nitroprusside dihydrate | 13755-38-9 | sc-203395 sc-203395A sc-203395B | 1 g 5 g 100 g | $43.00 $85.00 $158.00 | 7 | |
Sodium nitroferricyanide is a nitric oxide (NO) donor. It indirectly inhibits DDAH I by increasing the availability of NO. The elevated NO levels impact the feedback inhibition of DDAH I, leading to altered ADMA metabolism. The indirect inhibition by sodium nitroprusside involves modulation of the NO signaling pathway, influencing DDAH I activity and the levels of its substrate, asymmetric dimethylarginine (ADMA). | ||||||